• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

作者信息

Lee Jae Hoon, Lee Dong Soon, Lee Je Jung, Chang Yoon Hwan, Jin Jong Youl, Jo Deog-Yeon, Bang Soo Mee, Kim Hyo Jung, Kim Jin Seok, Kim Kihyun, Eom Hyeon Seok, Min Chang Ki, Yoon Sung Soo, Kim Sun Hee, Suh Cheolwon, Cho Kyung Sam

机构信息

Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon, Korea.

出版信息

Int J Hematol. 2010 Jul;92(1):52-7. doi: 10.1007/s12185-010-0617-6. Epub 2010 Jun 11.

DOI:10.1007/s12185-010-0617-6
PMID:20544403
Abstract
摘要

相似文献

1
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.韩国的多发性骨髓瘤：过去、现在及未来展望。韩国多发性骨髓瘤工作组的经验
Int J Hematol. 2010 Jul;92(1):52-7. doi: 10.1007/s12185-010-0617-6. Epub 2010 Jun 11.
2
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.多发性骨髓瘤治疗的演变及其对透析独立性的影响：来自法国1999年至2014年队列的数据。
Blood Cancer J. 2016 Mar 25;6(3):e409. doi: 10.1038/bcj.2016.17.
3
Five decades of therapy for multiple myeloma: a paradigm for therapeutic models.五十年的多发性骨髓瘤治疗：治疗模式的范例
Leukemia. 2005 Jun;19(6):910-2. doi: 10.1038/sj.leu.2403728.
4
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017.多发性骨髓瘤的发病率和生存率：基于人群的研究，纳入了 1982 年至 2017 年期间诊断的 10524 例患者。
Br J Haematol. 2020 Nov;191(3):418-425. doi: 10.1111/bjh.16674. Epub 2020 May 5.
5
Multiple myeloma.多发性骨髓瘤
Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.
6
Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.真实世界中大型全国健康计划中多发性骨髓瘤患者的流行病学、治疗模式和生存情况。
Leuk Res. 2019 Oct;85:106219. doi: 10.1016/j.leukres.2019.106219. Epub 2019 Aug 23.
7
Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.近十年多发性骨髓瘤患者的生存率显著提高：一项基于瑞典人群研究的结果
Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22.
8
Behind the Scenes of ESDR.电子皮肤疾病登记（ESDR）背后的故事
J Invest Dermatol. 2020 Sep;140(9S):S194-S196. doi: 10.1016/j.jid.2020.02.044.
9
Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.大剂量美法仑自体干细胞移植预处理后多发性骨髓瘤的早期复发疾病：一项基于2005年至2014年丹麦多发性骨髓瘤登记处的研究
Leukemia. 2018 Sep;32(9):2054-2057. doi: 10.1038/s41375-018-0057-5. Epub 2018 Feb 22.
10
Recent advances in multiple myeloma: a Korean perspective.多发性骨髓瘤的最新进展：韩国视角
Korean J Intern Med. 2016 Sep;31(5):820-34. doi: 10.3904/kjim.2015.408. Epub 2016 Sep 1.

引用本文的文献

1
Time trends in multiple myeloma incidence and mortality across the BRICS from 1992 to 2021 and projection to 2046.1992年至2021年金砖国家多发性骨髓瘤发病率和死亡率的时间趋势及到2046年的预测。
BMC Public Health. 2025 May 13;25(1):1765. doi: 10.1186/s12889-025-22688-2.
2
Real-world treatment patterns, outcomes, and economic costs by lines of therapy in patients with newly diagnosed multiple myeloma: a nationwide population-based cohort study in South Korea.新诊断多发性骨髓瘤患者按治疗线划分的真实世界治疗模式、结局及经济成本：韩国一项基于全国人群的队列研究
Blood Res. 2025 Apr 15;60(1):26. doi: 10.1007/s44313-025-00069-3.
3

本文引用的文献

1
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.来那度胺和硼替佐米治疗后复发的多发性骨髓瘤的进展和生存风险：一项多中心国际骨髓瘤工作组研究。
Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.
2
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.硼替佐米、多柔比星和地塞米松联合治疗后，沙利度胺和地塞米松巩固治疗作为复发或难治性多发性骨髓瘤的挽救治疗：疗效和安全性分析。
Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.
3
A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia.
关于亚洲多发性骨髓瘤流行病学及治疗选择的系统评价。
Heliyon. 2024 Oct 22;10(21):e39698. doi: 10.1016/j.heliyon.2024.e39698. eCollection 2024 Nov 15.
4
Real world evidence of epidemiological trends, clinical presentation, and prognostic outcomes of multiple myeloma (2007-2021).多发性骨髓瘤的流行病学趋势、临床表现及预后结果的真实世界证据（2007 - 2021年）
Front Med (Lausanne). 2024 Feb 20;11:1338552. doi: 10.3389/fmed.2024.1338552. eCollection 2024.
5
Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records.卡非佐米在韩国的真实世界安全性结局：基于电子健康记录的目标试验模拟研究。
Int J Environ Res Public Health. 2022 Oct 19;19(20):13560. doi: 10.3390/ijerph192013560.
6
Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.韩国多发性骨髓瘤患者免疫球蛋白基因重排：使用下一代测序进行克隆性评估和库分析。
PLoS One. 2021 Jun 24;16(6):e0253541. doi: 10.1371/journal.pone.0253541. eCollection 2021.
7
Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma.超声心动图定义的肺动脉高压对多发性骨髓瘤患者临床结局的临床影响
Medicine (Baltimore). 2020 Oct 23;99(43):e22952. doi: 10.1097/MD.0000000000022952.
8
Frontline therapy for newly diagnosed patients with multiple myeloma.新诊断多发性骨髓瘤患者的一线治疗
Blood Res. 2020 Jul 31;55(S1):S37-S42. doi: 10.5045/br.2020.S007.
9
Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd).在二线卡非佐米-来那度胺-地塞米松（KRd）方案后纳入造血干细胞移植。
Ther Adv Hematol. 2020 May 12;11:2040620720921046. doi: 10.1177/2040620720921046. eCollection 2020.
10
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.硼替佐米在复发或难治性多发性骨髓瘤患者真实临床环境中的治疗应用
Oncol Rev. 2019 Jan 18;13(1):377. doi: 10.4081/oncol.2019.377. eCollection 2019 Jan 14.
Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells.载有凋亡同种异体骨髓瘤细胞系的 Alpha 型 1 极化树突状细胞诱导针对自体骨髓瘤细胞的强烈 CTL 反应。
Ann Hematol. 2010 Aug;89(8):795-801. doi: 10.1007/s00277-010-0931-3. Epub 2010 Mar 18.
4
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.来那度胺联合地塞米松和环磷酰胺治疗初治多发性骨髓瘤的 II 期临床研究。
Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):62-7. doi: 10.3816/CLML.2010.n.007.
5
Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.韩国华氏巨球蛋白血症患者的分子细胞遗传学分析
Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008.
6
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).硼替佐米、沙利度胺、地塞米松诱导治疗后马法兰、泼尼松、沙利度胺巩固治疗，作为不适合移植的多发性骨髓瘤患者的一线治疗：韩国多发性骨髓瘤工作组（KMMWP）的结果。
Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10.
7
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.硼替佐米、环磷酰胺、沙利度胺和地塞米松（Vel-CTD）方案治疗复发或难治性多发性骨髓瘤患者的临床疗效：一项 II 期研究。
Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18.
8
Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.多发性骨髓瘤患者的临床特征与生存结局：来自韩国骨髓瘤登记处的基于网络数据的分析
Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29.
9
Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.在韩国多发性骨髓瘤患者中，沙利度胺治疗后临床明显血栓栓塞的发生率较低。
Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25.
10
Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.天然多酚通过直接化学相互作用拮抗蛋白酶体抑制剂硼替佐米的抗骨髓瘤活性。
Br J Haematol. 2009 Aug;146(3):270-81. doi: 10.1111/j.1365-2141.2009.07752.x. Epub 2009 Jun 3.